The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
Open accessAbstract
&NA; The costimulatory receptor 4‐1BB is expressed on activated immune cells, including activated T cells. Antibodies targeting 4‐1BB enhance the proliferation and survival of antigen‐stimulated T cells in vitro and promote CD8 T cell‐dependent anti‐tumor immunity in pre‐clinical cancer models. We found that T regulatory (Treg) cells infiltrating human or murine tumors expressed high amounts of 4‐1BB. Intra‐tumoral Treg cells were preferentially depleted by anti‐4‐1BB mAbs in vivo. Anti‐4‐1BB mAbs also promoted effector T cell agonism to promote tumor rejection. These distinct mechanisms were competitive and dependent on antibody isotype and Fc&ggr;R availability. Administration of anti‐4‐1BB IgG2a, which preferentially depletes Treg cells, followed by either agonistic anti‐4‐1BB IgG1 or anti‐PD‐1 mAb augmented anti‐tumor responses in multiple solid tumor models. An antibody engineered to optimize both Fc&ggr;R‐dependent Treg cell depleting capacity and Fc&ggr;R‐independent agonism delivered enhanced anti‐tumor therapy. These insights into the effector mechanisms of anti‐4‐1BB mAbs lay the groundwork for translation into the clinic. Graphical Abstract Figure. No caption available. HighlightsAnti‐4‐1BB IgG2a depletes intratumoral Treg cells; IgG1 promotes CD8 T cell functionThe efficacy of anti‐4‐1BB mIgG1 and anti‐4‐1BB mIgG2a depends on different Fc&ggr;RsOptimal tumor therapy requires sequential anti‐4‐1BB IgG2a and IgG1 or PD‐1 blockadeHinge‐engineered anti‐4‐1BB mIgG2a/h2B mAb harnesses both mechanisms of action &NA; Buchan et al. reveal dual anti‐tumor activities for antibodies to the co‐stimulatory receptor 4‐1BB, which depend on antibody isotype and Fc&ggr;R availability. Sequential scheduling of anti‐4‐1BB and checkpoint blockade mAbs, and antibodies engineered to harness both Treg cell depleting and effector cell agonism properties show potent anti‐tumor activity in preclinical models, laying the groundwork for translation into the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
CD4+CD25+ Immunoregulatory T Cells
McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395
Foxp3 occupancy and regulation of key target genes during T-cell stimulation
Marson, A., Kretschmer, K., Frampton, G. M., Jacobsen, E. S., Polansky, J. K., MacIsaac, K. D., Levine, S. S., Fraenkel, E., von Boehmer, H., & Young, R. A. (2007) · Nature · doi:10.1038/nature05478 · Cited by 724
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695
Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
Self-citation
Cited by
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01083-5 · Cited by 379
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Rodriguez-Garcia, A., Palazon, A., Noguera-Ortega, E., Powell, D. J., & Guedan, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01109 · Cited by 312
Gaspar, M., Pravin, J., Rodrigues, L., Uhlenbroich, S., Everett, K. L., Wollerton, F., Morrow, M., Tuna, M., & Brewis, N. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0798 · Cited by 58
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy
Cohen Saban, N., Yalin, A., Landsberger, T., Salomon, R., Alva, A., Feferman, T., Amit, I., & Dahan, R. (2023) · Science Immunology · doi:10.1126/sciimmunol.add8005 · Cited by 39
Metadata
- Authors
- Buchan, S. L., Dou, L., Remer, M., Booth, S. G., Dunn, S. N., Lai, C., Semmrich, M., Teige, I., Mårtensson, L., Penfold, C. A., Chan, H. T. C., Willoughby, J. E., Mockridge, C. I., Dahal, L. N., Cleary, K. L. S., James, S., Rogel, A., Kannisto, P., Jernetz, M., Williams, E. L., Healy, E., Verbeek, J. S., Johnson, P. W. M., Frendéus, B., Cragg, M. S., Glennie, M. J., Gray, J. C., Al-Shamkhani, A., & Beers, S. A.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 49
- Issue
- 5
- Pages
- 958-970.e7
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2901938738
- Cited by
- 160
- References
- 8
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.